Investors with the goal of beating the broader market often turn to stock selection. Strategic choices in individual stocks can have a profound impact on your wealth.
The price of Relay Therapeutics Inc (NASDAQ: RLAY) closed at $8.35 in the last session, down -0.71% from day before closing price of $8.41. In other words, the price has decreased by -$0.71 from its previous closing price. On the day, 1.14 million shares were traded. RLAY stock price reached its highest trading level at $8.395 during the session, while it also had its lowest trading level at $8.25.
Ratios:
We take a closer look at RLAY’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 19.14 and its Current Ratio is at 19.14. In the meantime, Its Debt-to-Equity ratio is 0.05 whereas as Long-Term Debt/Eq ratio is at 0.05.
On April 17, 2025, Wells Fargo started tracking the stock assigning a Equal Weight rating and target price of $4.Wells Fargo initiated its Equal Weight rating on April 17, 2025, with a $4 target price.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Nov 03 ’25 when Patel Sanjiv sold 62,073 shares for $7.00 per share. The transaction valued at 434,511 led to the insider holds 703,215 shares of the business.
Rahmer Peter sold 21,394 shares of RLAY for $160,455 on Oct 29 ’25. The insider now owns 337,469 shares after completing the transaction at $7.50 per share. On Oct 28 ’25, another insider, Rahmer Peter, who serves as the insider of the company, sold 19,135 shares for $7.29 each. As a result, the insider received 139,494 and left with 358,863 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RLAY now has a Market Capitalization of 1447241984 and an Enterprise Value of 884139904. For the stock, the TTM Price-to-Sale (P/S) ratio is 173.11 while its Price-to-Book (P/B) ratio in mrq is 2.37. Its current Enterprise Value per Revenue stands at 105.822 whereas that against EBITDA is -2.759.
Stock Price History:
The Beta on a monthly basis for RLAY is 1.56, which has changed by 0.955814 over the last 52 weeks, in comparison to a change of 0.17673707 over the same period for the S&P500. Over the past 52 weeks, RLAY has reached a high of $9.04, while it has fallen to a 52-week low of $1.77. The 50-Day Moving Average of the stock is 12.99%, while the 200-Day Moving Average is calculated to be 83.44%.
Shares Statistics:
According to the various share statistics, RLAY traded on average about 2.13M shares per day over the past 3-months and 2509210 shares per day over the past 10 days. A total of 172.63M shares are outstanding, with a floating share count of 130.41M. Insiders hold about 24.76% of the company’s shares, while institutions hold 74.71% stake in the company. Shares short for RLAY as of 1765756800 were 20296216 with a Short Ratio of 9.51, compared to 1763078400 on 21371170. Therefore, it implies a Short% of Shares Outstanding of 20296216 and a Short% of Float of 14.19.
Earnings Estimates
As of right now, 7.0 analysts gave their recommendation on the stock of the company. The consensus estimate for the next quarter is -$0.43, with high estimates of -$0.41 and low estimates of -$0.45.
Analysts are recommending an EPS of between -$1.5 and -$2.08 for the fiscal current year, implying an average EPS of -$1.74. EPS for the following year is -$1.61, with 6.0 analysts recommending between -$1.41 and -$1.78.
Revenue Estimates
A total of 10 analysts have provided revenue estimates for RLAY’s current fiscal year. The highest revenue estimate was $38.4M, while the lowest revenue estimate was $8M, resulting in an average revenue estimate of $12.77M. In the same quarter a year ago, actual revenue was $10.01M
